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Abstract: All skeletal bones house osteogenic stem cell niches, in which mesenchymal stromal cells
(MSC) provide progenitors for tissue growth and regeneration. They have been widely studied
in long bones formed through endochondral ossification. Limited information is available on the
composition of the osteogenic niche in flat bones (i.e., skull vault bones) that develop through
direct membranous ossification. Craniosynostosis (CS) is a congenital craniofacial defect due to
the excessive and premature ossification of skull vault sutures. This study aimed at analysing the
expression of GLI1, AXIN2 and THY1 in the context of the human skull vault, using nonsyndromic
forms of CS (NCS) as a model to test their functional implication in the aberrant osteogenic process.
The expression of selected markers was studied in NCS patients’ calvarial bone specimens, to assess
the in vivo location of cells, and in MSC isolated thereof. The marker expression profile was analysed
during in vitro osteogenic differentiation to validate the functional implication. Our results show that
GLI1 and AXIN2 are expressed in periosteal and endosteal locations within the osteogenic niche of
human calvarial bones. Their expression is higher in MSC isolated from calvarial bones than in those
isolated from long bones and tends to decrease upon osteogenic commitment and differentiation.
In particular, AXIN2 expression was lower in cells isolated from prematurely fused sutures than
in those derived from patent sutures of NCS patients. This suggests that AXIN2 could reasonably
represent a marker for the stem cell population that undergoes depletion during the premature
ossification process occurring in CS.
Keywords: mesenchymal stromal cells; stem cell niche; GLI1; AXIN2; osteogenesis; bone development;
nonsyndromic craniosynostosis; cranial suture; regenerative medicine; personalised medicine
1. Introduction
Craniofacial bones are flat bones formed through intramembranous ossification, differently from
most of the other bones of the human skeleton that develop through endochondral ossification [1].
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Intramembranous bone ossification is indeed a direct process in which osteoblasts differentiate directly
from mesenchymal cells, without the formation of cartilage precursors.
In the craniofacial region, intramembranous bone development starts with the aggregation
of mesenchymal stromal cells (MSC) into condensation centres, where they grow and proliferate,
forming clusters [2]. Once the cluster reaches a critical size, MSC in the centre start to differentiate
into osteoblasts. The growth of immature bone occurs at the osteogenic fronts, where cells actively
proliferate. When an osteogenic front joins its neighbour, the two fronts either merge to create a single
bone or give rise to a suture [3].
A suture is hence a fibrous joint composed of two osteogenic fronts and the interposed
mesenchyme-derived fibrous tissue, which provides flexibility to the newborn skull and acts as
an active site of bone formation during skull development in the first two years of life [4,5]. Sutures
persist afterwards in toddlers and young adults, as elastic skull sites until flat bone ossification
is complete and skull growth ceases, having reached its final size. The inter-suture mesenchyme
represents indeed a unique niche for cranial skeletal stem cells, serving as a transient reservoir
of MSC and osteoprogenitors [6]. These MSC play a key role in regulating the skull growth:
proliferating cells produce new progenitors to support skull growth while a quiescent portion of
the MSC population remains in the centre to preserve suture patency and to modulate calvarial
bone growth [7]. The osteogenic fate of MSC residing in the suture is driven by the interplay of
a complex signalling (including WNT, BMP, FGF and HH pathways as main players) [7–10] that govern
the homeostasis of the calvarial osteogenic niche, essential for calvarial morphogenesis [3,6,10,11].
The disruption of the gene expression pattern and/or of the signalling inside the niche could affect
the balance among quiescence–proliferation–differentiation–apoptosis within the suture mesenchyme,
causing abnormalities in skull development.
The premature ossification of skull sutures causes craniosynostosis (CS), the second most common
congenital craniofacial defect, affecting 1 in ~2500 live births [12,13]. Individuals with CS develop
abnormal skull shapes due to premature fusion of one or more cranial sutures, leading to variable
degrees of craniofacial dysmorphisms, along with possible increase of intracranial pressure and, in the
most severe cases, neurodevelopmental delay. CS occurs in 85% of cases as an isolated and sporadic
(i.e., nonfamilial) disorder, in which the abnormal suture fusion apparently results from a developmental
defect that directly targets the affected suture(s), without affecting the rest of the body, being hence
classified as nonsyndromic craniosynostosis (NCS). NCS is considered a multifactorial disorder,
in which gene–gene and/or gene–environment interaction effects are plausibly involved, although their
aetiopathogenesis is still largely unclear [8,14–17]. The complex nature of craniosynostosis is reflected
by the difficulty in obtaining univocal therapeutic protocols. To date, the only available therapeutic
approach is based on single or repeated reconstructive surgeries, depending on the complexity of the CS
and the presence of associated co-morbidities and/or the occurrence of unsatisfying or adverse surgical
outcomes [18–21]. Consequently, understanding the human postnatal craniofacial development
and growth and its underlying molecular control is critical for developing adjuvant and possibly
personalised therapeutic strategies.
Once their development is completed, craniofacial bones are formed by two layers of compact
bone (inner and outer tables) that enclose a sheet of spongy bone (diploe), housing bone marrow
(BM) cavities. In this mature bone structure, osteogenic niches are located, as for other bones, in the
cambium layer of the periosteum and in the endosteum, which forms the lining of bone marrow cavity
walls [6]. The endosteal osteogenic niche is believed to include osteoblasts, endothelial cells, glial cells,
vascular pericytes, adipocytes, fibroblasts and MSC [22] The osteogenic and haematopoietic stem
cell niches are hence functionally related within the BM environment of the diploe, as MSC support,
and regulate the homing of haematopoietic stem cells (HSC), and HSC provide osteoclast precursors
that combine with osteogenic lineage’s cells to form the bone structure [23]. Therefore, altogether the
calvarial bones’ niches include at least three distinct domains: the endosteal and periosteal domains,
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which are necessary to accomplish the skull remodelling throughout life, and the transient suture
mesenchyme domain that disappear as suture ossify in adult life [6] (Figure 1).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 20 
 
 
Figure 1. Visual description of the architecture of calvarial flat bone. Two sheets (outer and inner 
tables) of compact bone enclose a layer of spongy bone (diploë). Green arrows highlight the endosteal, 
periosteal and inter-suture locations of MSC niches (figure modified from https://smart.servier.com/). 
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differences among different skeletal niches has been long neglected and is yet pending, owing to the 
inherent cellular heterogeneity, to the different bone developmental path occurring throughout the 
skeleton, and to the difficulties in studying suitable human flat bone tissues. Recent studies have 
indeed demonstrated that MSC have distinctive features depending on their in vivo location [24,25]. 
An in-depth functional characterisation of the osteogenic stem cell niche composition and their 
involvement in skeletal development was provided by Chan and colleagues, who studied limb bones 
and bone marrow tissues of foetal, neonatal and adult mice [26]. This study allowed identifying four 
functionally distinct cell fractions: a CD45+ haematopoietic fraction, a CD45-Tie2 (angiopoietin 
receptor)+ alpha V integrin (alphaV)+ population that concurrently generates adipocytes and vessels, 
a CD45-Tie2-alphaV- fraction that does not appear to produce donor-engrafted tissue and a CD45-
Tie2-alphaV+ population that, through endochondral ossification, forms bone endowed with bone 
marrow cavities [26].  
Calvarial stem cell research has been largely driven by the identification of specific markers 
expressed by resident populations. In recent years, three distinct cell populations were identified, 
based on the lineage-specific expression of selected marker genes (namely, GLI1, AXIN2 and THY1), 
within the sutural mesenchyme of murine models, and proposed as major calvarial skeletal stem 
cells, or subsets of it [27].  
GLI1 (GLI Family Zinc Finger 1), a transcriptional key effector of Hedgehog (HH), has been 
recently proposed as the main marker for the mesenchymal stem cell population in mice, responsible 
for adult craniofacial bone growth and development [11]. The AXIN2 protein acts as a negative 
regulator of the Wnt signalling and has been previously implicated in murine calvarial 
morphogenesis [28]. More recently, the presence of an AXIN2-expressing stem cell population was 
demonstrated in murine calvarial bones [29]. AXIN2+ cells proved to have long-term self-renewing 
clonal expansion and differentiation capabilities during calvarial development, suggesting that 
AXIN2 should be a suitable specific marker for calvarial bone stem cells [29]. Finally, PRX1 (Paired 
Related Homeobox 1) is a DNA-binding protein expressed in mesodermal tissues, acting as a 
transcriptional co-activator, implicated in the maintenance of cell fates within the craniofacial 
mesenchyme. PRX1-expressing cells were shown to reside exclusively in the calvarial suture niche 
and to decrease in number with age [4]. Interestingly, PRX1 expression seemed to be involved in 
differentiation of early progenitors into committed osteoblasts, suggesting that this transcription 
factor could specify the stem cell population in calvarial bones [30]. Taken together, all available data 
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tables) of compact bone enclose a layer of spongy bone (diploë). Green arrows highlight the endosteal,
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cells were shown to reside exclusively in the calvarial suture niche and to decrease in number with
age [4]. Interestingly, PRX1 expression seemed to be involved in differentiation of early progenitors into
committed osteoblasts, suggesting that this transcription factor could specify the stem cell population
in calvarial bones [30]. Taken together, all available data are extremely heterogeneous and not clearly
reproducible, hence a calvarial stem cell population is yet to be defined [4,11,29,30].
Moreover, the data available thus far are derived exclusively from studies performed in mice,
whose skull bone structure is extremely thin and less layered than in humans. The structure and
control of the human calvarial osteogenic niche has not been studied, to date, highlighting a gap of
knowledge in the definition of adult stem cells responsible for calvarial bone formation and endogenous
regeneration properties.
Our group previously isolated and characterised a population of human multipotent MSC-like
cells from suture tissues of patients undergoing surgery for treating NCS [31]. Cells isolated from fused
sutures showed a higher osteogenic potential, compared with cells isolated from patient-matched
unfused sutures, owing to the constitutive activation of the BMP-dependent signalling [31] and the
alteration of the GLI1 expression pattern and related primary cilium signalling [32].
The aim of the present study was to characterise the calvarial MSC and the corresponding niche
using NCS patients’ specimens as a model to identify the human craniofacial bone stem cell population.
By comparing tissues and cells of fused-versus-unfused sutures of patients, we also aimed to shed
light on the pathophysiology of the disease, hence to identify potential cellular and molecular targets
to be translated into non-invasive/adjuvant therapeutic strategies. To this aim, the expression of
selected markers was analysed in NCS patients’ calvarial bone specimens and in the MSC isolated
thereof. Our results indicate the presence of an identifiable calvarial MSC population expressing
a specific molecular profile that is dysregulated in fused suture sites, showing abnormal osteogenic
differentiation properties. In particular, our data provide evidence that GLI1- and AXIN2-expressing
cells reasonably represent the osteogenic stem cells within the human calvarial bone niche.
2. Results
2.1. Localisation of Calvarial Stem Cell Markers in Suture Tissue Samples
The expression pattern of AXIN2 and GLI1 in calvarial bone specimens was analysed by
immunofluorescence in unfused- and fused-suture tissue samples derived from sagittal NCS patients.
In particular, the two markers were tested in a double staining with either the Ki-67 proliferation
marker or the THY1 MSC surface antigen, with the aim to assess the presence of a proliferating MSC
subpopulation positive also for AXIN2 and GLI1.
AXIN2-related fluorescence was intensely visible on the periosteal lining and discontinuously
expressed on the endosteal side of spongy bone’s trabeculae (Figure 2). Ki-67 was prevalently expressed
along the endosteal lining of the diploic trabeculae, with spread spots also visible on the inner periosteal
layer on the outer compact bone table (Figure 2b,c and Figure 3b,c). THY1 was scarcely expressed on
both endosteal and periosteal sites (Figure 2d,e and Figure 3d,e).
Conversely, GLI1 expression was visible along the periosteal layer of both the outer and the inner
tables and on the endosteal surfaces of the diploic trabeculae (Figure 3).
The double staining allowed observing a subpopulation of AXIN2+/THY1+ and AXIN2+/Ki-67+
cells mostly along the endosteal lining of the trabeculae (Figure 2). As for AXIN2, GLI1 +/Ki-67+
co-expression appeared visible mostly on the endosteal side in the trabecular bone (Figure 3). Above all,
a subpopulation of GLI1+/THY1+ cells was present in the endosteal side and along the trabeculae’s
margins (Figure 3). In particular, our analysis also showed that there was no remarkable difference in
the colocalisation of GLI1 and THY1 between fused and unfused tissue sections (Figure 3).
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Figure 2. AXIN2 and THY1 expression in calvarial bone. (a) The haematoxylin/eosin staining displays 
the histological structure of a cross-section of the flat calvarial bone, showing the periosteum and 
endosteum location. Localisation of AXIN2/Ki-67 and AXIN2/THY1 expression in (b,c) fused and 
(d,e) unfused suture tissue sections, assessed by immunofluorescence. Green arrows highlight 
AXIN2+ cells, red arrows point out (b,d) Ki-67+ cells and (c,e) THY1+ cells. Yellow arrows indicate 
AXIN2+/THY1+ and AXIN2+/Ki-67+ cells. Pictures are representative of 90 microscopic fields from 
nine slides (technical replicates) at 20× magnification of three patients (biological replicates) (see 
Methods for details). 
Figure 2. AXIN2 and THY1 expression in calvarial bone. (a) The haematoxylin/eosin staining displays
the histological structure of a cross-section of the flat calvarial bone, showing the periosteum and
endosteum location. Localisation of AXIN2/Ki-67 and AXIN2/THY1 expression in (b,c) fused and (d,e)
unfused suture tissue sections, assessed by immunofluorescence. Green arrows highlight AXIN2+ cells,
red arrows point out (b,d) Ki-67+ cells and (c,e) THY1+ cells. Yellow arrows indicate AXIN2+/THY1+
and A I 2 /Ki-67 cells. Pictures are representative of 90 microscopic fields from nine slides (technical
replicat s) at 20×magnification of three patients (biological plicat s) (see Methods for details).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 20 
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MSC (BM-MSC) isolated from the iliac crest and grown in standard culture condition as “gold 
standard” osteogenic MSC controls. The expression of THY1 and ITGAV was comparable among the 
three tested cell types (Figure 4a,b), whereas the expression of TEK showed a reduced trend in CMSC 
compared with BM-MSC, although the differential expression levels reached statistical significance 
only in P-CMSC (Figure 4c). The expression of ENPEP showed an inverted trend, as it was 
significantly upregulated in P-CMSC over BM-MSC, with an increased trend also in N-CMSC over 
BM-MSC (no statistical significance; Figure 4d). GLI1 expression was significantly overexpressed 
over BM-MSC in both N- and P-CMSC (Figure 4e). Finally, AXIN2 was significantly overexpressed 
in N-CMSC compared with BM-MSC (Figure 4f). Interestingly, the expression of AXIN2 resulted 
significantly lower in P-CMSC over N-CMSC (Figure 4f). 
Figure 3. GLI1 and THY1 expression in calvarial bone. (a) The haematoxylin/eosin staining displays
the histological structure of a cross-section of the flat calvarial bone, showing the periosteum and
Int. J. Mol. Sci. 2020, 21, 4356 6 of 19
endosteum location. Localisation of GLI1/Ki-67 and GLI1/THY1 in (b,c) fused and (d,e) unfused suture
tissue sections, assessed by immunofluorescence. Green arrows highlight cells GLI1+, red arrows point
out (b,d) Ki-67+ cells and (c,e) THY1+ cells. Yellow arrows indicate GLI1+/THY1+ and GLI1+/Ki-67+
cells. The haematoxylin/eosin staining displays the histological structure of the flat calvarial bone.
Pictures are representative of 90 microscopic fields from nine slides (technical replicates) at 20×
magnification of three patients (biological replicates) (see Methods for details).
2.2. Expression of Calvarial Stem Cell Markers in Calvarial Mesenchymal Stromal Cells (CMSC)
The expression of the selected marker genes THY1, ITGAV, TEK, ENPEP, GLI1 and AXIN2
was analysed in calvarial MSC isolated both from physiologically patent sutures (termed “Normal”,
N-CMSC) and from prematurely fused sutures (termed “Pathologic”, P-CMSC), using bone marrow
MSC (BM-MSC) isolated from the iliac crest and grown in standard culture condition as “gold standard”
osteogenic MSC controls. The expression of THY1 and ITGAV was comparable among the three tested
cell types (Figure 4a,b), whereas the expression of TEK showed a reduced trend in CMSC compared with
BM-MSC, although the differential expression levels reached statistical significance only in P-CMSC
(Figure 4c). The expression of ENPEP showed an inverted trend, as it was significantly upregulated
in P-CMSC over BM-MSC, with an increased trend also in N-CMSC over BM-MSC (no statistical
significance; Figure 4d). GLI1 expression was significantly overexpressed over BM-MSC in both N-
and P-CMSC (Figure 4e). Finally, AXIN2 was significantly overexpressed in N-CMSC compared with
BM-MSC (Figure 4f). Interestingly, the expression of AXIN2 resulted significantly lower in P-CMSC
over N-CMSC (Figure 4f).
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being considerably upregulated upon osteogenic induction at both tested time points (Figure 6c,f). 
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ON; (d,i) OPN; and (e,j) OCN, evaluated by qPCR in N-CMSC and P-CMSC, respectively, cultured 
with osteogenic medium (OM) for one (1 wk) and three weeks (3 wk). Cells cultured in standard 
growth medium (GM) were tested as controls at each time point. RQ, Relative Quantity (see Methods 
for details). *p < 0.05; **p < 0.01; ****p < 0.0001. 
Figure 4. Comparative expression profiling of marker genes in iliac crest BM-MSC and suture cells
CMSC. Transcript levels of: (a) THY1; (b) ITGAV; (c) TEK; (d) ENPEP; (e) GLI1; and (f) AXIN2, evaluated
by qPCR in N- and P-CMSC, compared with BM-MSC. RQ, Relative Quantity (see Methods for details).
* p < 0.05; ** p < 0.01; **** p < 0.0001.
2.3. Expression of Calvarial Stem Cell Markers during Osteogenic Induction
Both N- and P-CMSC were efficiently induced toward osteoge ic induction up to three weeks,
as demonstrated by the upregulation of the osteo-specific marker genes RUNX2, ALP, ON, OPN and
OCN (Figure 5). The expression of THY1, GLI1 and AXIN2 were observed in time course. THY1 and
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GLI1 levels were significantly downregulated in committed N- and P-CMSC after both one and three
weeks (Figure 6a,b,d,e). In contrast, AXIN2 expression was comparable between N- and P-CMSC,
being considerably upregulated upon osteogenic induction at both tested time points (Figure 6c,f).
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Figure 5. Expression profiles of osteo-specific genes. Transcript levels of: (a,f) RUNX2; (b,g) ALP;
(c,h) ON; (d,i) OPN; and (e,j) OCN, evaluated by qPCR in N-CMSC and P-CMSC, respectively, cultured
with osteogenic medium (OM) for one (1 wk) and three weeks (3 wk). Cells cultured in standard
growth medium (GM) were tested as controls at each time point. RQ, Relative Quantity (see Methods
for details). * p < 0.05; ** p < 0.01; **** p < 0.0001.
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GLI1; and (c,f) AXIN2, evaluated by qPCR in N-CMSC and P-CMSC, respectively, cultured with 
osteogenic medium (OM) for one (1 wk) and three weeks (3 wk). Cells cultured in standard growth 
medium (GM) were tested as controls at each time point. RQ, Relative Quantity (see Methods for 
details). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
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differentiation process (Figures 7 and 8). In particular, GLI1 protein staining was clearly detectable 
in the cell nuclei and showed a remarkable decrease as early as one week after starting the osteogenic 
stimulation, being barely detectable after three weeks, in both N- and P-CMSC (Figure 7d,h). Both 
THY1 and AXIN2 were diffusely expressed in the cytoplasm of cells and tended to decrease during 
osteogenic induction (see Figures 7a–c, e–g and 8a–c, e–g). The timing of THY1 decrease was 
comparable in N- and P-CMSC as detected by quantitative estimation of cell staining (data not 
shown). AXIN2 expression was intense and diffuse in the cell cytoplasm; it appeared apparently 
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Figure 6. Expression profiles of putative niche marker genes. Transcript levels of: (a,d) THY1; (b,e) GLI1;
and (c,f) AXIN2, evaluated by qPCR in N-CMSC and P-CMSC, respectively, cultured with osteogenic
medium (OM) for one (1 wk) and three weeks (3 wk). Cells cultured in standard growth medium (GM)
were tested as controls at each time point. RQ, Relative Quantity (see Methods for details). * p < 0.05;
** p < 0.01; *** p < 0.001; **** p < 0.0001.
To confirm the gene expression profile, THY1, GLI1 and AXIN2 protein levels were analysed and
quantified in situ using immunofluorescence during osteogenic induction. Our results revealed that the
expression of all the analysed markers was significantly reduced throughout the in vitro differentiation
process (Figures 7 and 8). In particular, GLI1 protein staining was clearly detectable in the cell nuclei
and showed a remarkable decrease as early as one week after starting the osteogenic stimulation,
being barely detectable after three weeks, in both N- and P-CMSC (Figure 7d,h). Both THY1 and AXIN2
were diffusely expressed in the cytoplasm of cells and tended to decrease during osteogenic induction
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(see Figure 7a–c,e–g and Figure 8a–c,e–g). The timing of THY1 decrease was comparable in N- and
P-CMSC as detected by quantitative estimation of cell staining (data not shown). AXIN2 expression
was intense and diffuse in the cell cytoplasm; it appeared apparently unaffected by the osteogenic
induction in N-CMSC at one week (Figure 8d), while it significantly decreased in P-CMSC at the same
time point (Figure 8h). Thereafter, AXIN2 expression significantly decreased in both N- and P-CMSC
at three weeks (Figure 8d,h).
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Figure 7. Expression of GLI1 and THY1 in CMSC during osteogenic induction. Markers’ expression
analysed by immunofluorescence in (a–c) N-CMSC and (e–g) P-CMSC, cultured with osteogenic
medium (OM) for one (1 wk) and three weeks (3 wk), compared to cells cultured in growth medium
(GM). Nuclei are stained in blue with DAPI. The intensity of fluorescence was quantified by the ImageJ
software for both (d) N-CMSC and (h) P-CMSC. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Pictures are representative of 30 microscopic fields of three different cell culture samples (see Methods
for details).
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analysed by immunofluorescence in (a–c) N-CMSC and (e–g) P-CMSC, cultured with osteogenic
medium (OM) for one (1 wk) and three weeks (3 wk), compared to cells cultured in growth medium
(GM). Nuclei are stained in blue with DAPI. The intensity of fluorescence has been quantified by
the ImageJ software for both (d) N-CMSC and (h) P-CMSC. * p < 0.05; ** p < 0.01; *** p < 0.001;
**** p < 0.0001. Pictures are representative of 30 microscopic fields of three different cell culture samples
(see Methods for details).
2.4. AXIN2 Involvement in the Ossification Process in NCS
Since our results show a differential expression of AXIN2 in P-CMSC and N-CMSC (see Figure 4),
we tried to derive possible implications for the pathophysiology of NCS. More in detail, our analysis
displayed that AXIN2 expression was lower in P-CMSC compared with N-CMSC both in standard
growth and during osteogenic induction, at both tested time points (Figure 9a). Instead, AXIN2 protein
levels were comparable in N- and P-CMSC cultured in growth medium (Figure 9b). Remarkably,
AXIN2 expression decreased earlier in P-CMSC compared with N-CMSC upon osteogenic induction
(Figure 9b). Taken together, these data indicate that, even though AXIN2 was modulated in response
to osteogenic commitment in both N- and P-CMSC, the effect was faster and more evident in cells
derived from pathologically fused sutures (Figure 9a,b).
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Figure 9. Comparative expression profiling of AXIN2 gene and protein in N-versus-P-CMSC.
(a) T anscript and (b) protein levels of AXIN2 compared in P-CMSC versus N-CMSC, in standard
growth conditions (GM) and following one (1 wk) and three weeks (3 wk) of osteogenic commitment
(OM). RQ, Relative Quantity (see Methods for details). * p < 0.05; ** p < 0.01; *** p < 0.001.
To better clarify this differential modulation of AXIN2 in NCS during the osteogenic process,
we knocked down the expression of AXIN2 in N-CMSC by means of short interfering RNAs (siRNAs),
to test whether this could induce an accelerated osteogenic phenotype as seen in P-CMSC in vitro [31].
Gene silencing reduced AXIN2 expression by 35% (Figure 10a, si-N-CMSC RQ mean: 0.64). The use of
higher dosage of siRNAs for AXIN2 led to a drastic reduction of cell viability after treatment; therefore,
the dosage scale was reduced. Interestingly, when AXIN2 expression in N-CMSC reached levels
comparable to that observed in P-CMSC (Figure 10a), this induced the differential expression of selected
osteo-specific marker genes upon one week of osteogenic induction (Figure 10b–e). In particular,
our analysis showed that the relative quantity of RUNX2, ON, OPN and OCN observed in silenced
N-CMSC (si-N-CMSC) was significantly different from that observed in untreated N-CMSC, while it
followed an expression trend comparable with that observed in P-CMSC (Figure 10b,d–f). Only the
expression of ALP showed an opposite trend in si-N-CMSC, being decreased, and in P-CMSC,
being upregulated, compared to N-CMSC (Figure 10c). The mock-treatment using exclusively the
transfection reagent did not affect the expression of the tested genes at any time point (data not shown).
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Figure 10. AXIN2 knockdown results. Expression analysis of: (a) AXIN2; (b) RUNX2; (c) ALP; (d) ON;
(e) OPN; and (f) OCN, evaluated by qPCR upon AXIN2 silencing in N-CMSC (si-N-CMSC) cultured
with osteogenic medium for one week (OM 1wk). Untreated N-CMSC were used as controls for both
si-N-CMSC and P-CMSC. The graphs show the average values derived from three different experiments
on three different patient’s derived cells. RQ, Relative Quantity (see Methods for details). * p < 0.05;
** p < 0.01; *** p < 0.001.
3. Discussion
The idea that a non-haematopoietic multipotent stem cell population resides in the bone marrow
(BM) dates back in the early 20th century, with the emerging evidence of the presence of BM
stroma-derived cells able to generate tissues of the mesodermal lineages such as bone [33,34]. Since then,
the mesenchymal stromal cell (MSC) compartment has been widely characterised within the BM niche
found in endochondral bones of the appendicular skeleton of murine models.
Recent studies attempted the characterisation of the MSC compartment of skull flat bones,
describing a calvarial MSC niche responsible for the correct morpho-functional skull development.
Thus far, research performed in mice highlighted the presence of specific markers, namely Gli1, Axin2
and Prx1, able to efficiently discriminate the MSC population in the cranial bones [4,11,29].
The novelty of the present work resides in that the MSC subpopulation was characterised for the
first time in human calvarial bones, and in the assessment of the potential involvement of this bone
niche in the pathophysiology of abnormal suture ossification occurring as an isolate developmental
defect in nonsyndromic craniosynostosis.
All adult stem cell niche specialised compartments are known to undergo a physiological
age-related decline, resulting in the reduced abilities of adult stem cells to sustain quiescence,
proliferation capacity and differentiation potential. In craniosynostosis, the calvarial suture stem
cells niche is believed to undergo an accelerated and premature senescence, causing a pathological
exhaustion of the stem cell reservoir, which ultimately drives the premature ossification of the suture
mesenchyme [35].
Our study provides the original evidence of the presence of a GLI1+ MSC subpopulation in
the craniofacial bone specimens of patients suffering from nonsyndromic craniosynostosis. GLI1 is
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a transcription factor that regulates the Hedgehog (HH) transmembrane receptor Patched PTCH1,
in the “canonical” modulation of the HH pathway [36]. The link between HH and the skeletal
development have been extensively investigated [37–39]. In particular, HH signalling plays a key role
in intramembranous ossification during cranial bone development [40]. Alterations in HH pathway
regulation were well documented in several craniofacial abnormalities, including craniosynostosis [40].
Our results demonstrate the presence of a GLI1+ cell subpopulation in the trabecular bone of
human cranial tissue samples. The expression of GLI1 in calvarial MSC isolated from fused and
unfused suture tissues of NCS patients resulted significantly higher compared with MSC isolated from
hip bone’s bone marrow specimens. These data may point towards defining GLI1 as a putative specific
marker for MSC inside the human calvarial niche, representing the osteogenic stem cells supporting the
craniofacial bone development inside the human cranial tissue, as already found in murine models [11].
On the other hand, no differences in GLI1 levels were detectable between CMSC derived from fused
sutures and those from the unfused one, suggesting that this marker is homogeneously expressed by
cells that are not affected by the niche ageing process. Moreover, GLI1 decreased during the in vitro
osteogenic induction showing an expression trend that overlaps with that of THY1, a cell surface
glycoprotein, widely used as marker of mesenchymal stromal cells, and inversely correlated with the
acquisition of the osteogenic committed phenotype.
In our disease model, we observed that the distribution of AXIN2-expressing cells within the
human calvarial niche is comparable between normal and pathological suture specimens, and found
in anatomical regions already described in murine models [28,29]. AXIN2 is a negative regulator of
the canonical Wnt/β-catenin pathway: AXIN2 transcription increases upon transduction of a Wnt
signal and it provides a negative feedback loop on the pathway, by promoting the degradation
of β-catenin [41]. Wnt/β-catenin signalling controls skeletal precursors’ renewal and proliferation
and their commitment [10]. AXIN2 is specifically involved in skull development, as it regulates
calvarial suture closure [28]. It has been demonstrated that Axin2 mutant mice present a phenotype
resembling craniosynostosis [28,42,43]. In particular, the inactivation of Axin2 causes an acceleration
in osteogenesis, leading to a premature metopic suture closure [28]. Indeed, evidence obtained in
murine models showed that Axin2 is mainly expressed in the osteogenic fronts and in the periosteum,
where pre-osteoblasts and osteoblasts are located, and its expression starts decreasing as the suture
fusion process starts, being absent in the fused suture [28,29].
Our data indicate that AXIN2 transcript levels are lower in cells isolated from fused sutures than
in those from physiologically patent sutures. AXIN2 expression resulted modulated during osteogenic
induction in all tested cells, although both transcript and protein levels were significantly lower in
pathologically fused suture-derived cells. Moreover, AXIN2 knockdown in N-CMSC induces the
activation of genes involved in the osteogenic commitment and differentiation of MSC. In particular,
our data reveal that the expression of osteo-specific genes induced in N-MSC upon AXIN2 silencing
is comparable to that of observed in P-CMSC during in vitro osteogenic induction. This evidence
may confirm that AXIN2 can represent a reliable marker for the stem cell population that undergoes
depletion during the premature ossification process occurring in craniosynostosis. Consistently with
our results, a de novo loss-of-function mutation in AXIN2 gene has been recently reported in a patient
diagnosed with sagittal craniosynostosis [44].
Nonetheless, our data also show that AXIN2 transcript levels increase, whereas AXIN2 protein
levels decrease, in response to in vitro osteogenic differentiation. Further investigation is necessary
to interpret this apparent discrepancy, which could be linked to a possible post-transcriptional
regulation of AXIN2 (involving RNA processing, trafficking, or decay mechanisms). Such events, to
our knowledge, have not been reported in the extant literature.
Finally, the data presented in this study indicate that calvarial MSC isolated from both fused and
unfused sutures share the same expression profile for the selected marker genes, upon in vitro isolation
through explant culture. This evidence may suggest that the “stemness”-related profile of the cells is
not affected by the collection site.
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On the other hand, we and other groups previously demonstrated that cells isolated from fused
sutures of NCS tend to display a constitutively increased osteogenic activity compared to those
isolated from open sutures [17,31,32,45–51]. This differential osteogenic activity was also observed
in fused-versus-unfused suture-derived cells of patients diagnosed with Saethre–Chotzen syndrome,
an autosomal dominant CS due to TWIST1 loss-of-function mutations [52]. This suggests that local
functional abnormalities exist at the site of premature suture fusion, even in the presence of documented
germline genetic background shared by all cells.
Taken together, these observations indicate that the tissue-specific niche is inherently preserved
(i.e., the same in unfused and fused) in NCS, and the cells maintain the same molecular signature
after in vitro isolation, but then local microenvironmental clues provide aberrant stimuli to the cells at
the site of the prematurely fused/fusing sutures. Hence, differences in the microenvironment able to
modify the niche homeostasis could be responsible for the enhanced in vivo osteogenic differentiation
acting at the site of premature suture closure, besides constitutive differences in stem cell properties.
This speculative hypothesis is further supported by some recent studies showing that an environmental
constraint in vitro induces a specific gene expression profile mimicking that expressed by NCS fused
suture-cells [53–55].
4. Materials and Methods
All reagents used were purchased from Aurogene (Rome, Italy), if not otherwise specified.
4.1. Patient Enrolment and Specimen Collection
We enrolled a sample of 23 patients (mean age 4.7 months; median 4 months; ratio male:female
3.6:1) undergoing cranioplastic surgery for nonsyndromic sagittal craniosynostosis, upon obtaining
the written informed consent from their parents.
Suture tissue specimens were collected from both the physiological patent suture (unfused, termed
“Normal”, N) and two from the prematurely fused suture (termed “Pathologic”, P) of patients as
surgical waste tissues. The sample collected from each suture site was aliquoted into two separate
specimens: one placed in culture medium to be used for cell isolation and the other one fixed in
formalin and used for immunofluorescence assays. The entire study protocol was designed according
to the European Good Clinical Practice guidelines and with the current revision of the Declaration of
Helsinki, and was approved by the Ethical Committee of the Università Cattolica del Sacro Cuore,
School of Medicine (17 July 2014; protocol NIH/NIDCR 2014, protocol 19029/14).
4.2. Calvarial Mesenchymal Stromal Cells (CMSC) Isolation and Culture
CMSC were isolated in primary culture from each tissue specimen (“Normal” N-CMSC;
“Pathologic” P-CMSC) harvested from patients and cultured as previously described [31]. Our standard
procedure allows selecting adherent cells from the flat bone suture boundary, regardless of the suture
ossification status. These cells displayed the phenotype and biological properties of mesenchymal
stromal cells (including a CD29+/CD44+/CD105+/CD73+/CD34−/CD31−phenotype and trilineage
potential) [31].
Upon reaching confluence, primary cells were detached with trypsin/EDTA and sub-cultivated
until the 3rd passage to amplify the cell population and used in further experiments. Mesenchymal
stromal cells isolated from human iliac crest bone marrow samples (BM-MSC), representing the gold
standard source for MSC isolation, were used as controls.
4.3. Osteogenic Induction
The in vitro osteogenic induction assay was performed as previously described [31]. Briefly,
both N-CMSC and P-CMSC at the 3rd–4th culture passage grown until confluence were cultured in
osteogenic medium (OM; Dulbecco’s Modified Eagle’s Medium Low Glucose (DMEM), 10% foetal
bovine serum (FBS, GIBCO by ThermoFisher Scientific, Waltham, MA, USA), 1% l-glutamine,
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1% penicillin–streptomycin, dexamethasone 0.1 µM, β-glycerophosphate (Sigma Aldrich, Saint Louis,
MO, USA) 10 µM and ascorbic acid 50 µM, for one (1 wk) and three weeks (3 wk). Medium was
changed twice a week. Cells cultured in standard growth medium (DMEM High Glucose, 10% FBS,
1% l-Glutamine and 1% Penicillin-Streptomycin) were used as negative controls for differentiation (GM).
4.4. Gene Expression Analysis
Total RNA was isolated from N- and P-CMSC and BM-MSC at different time points, using
Trizol regent (ThermoFisher Scientific, Waltham, MA, USA) following manufacturer’s protocol and
subsequently purified using silica membrane spin columns (ReliaPrep RNA™ Cell Miniprep System
Promega, San Luis Obispo, CA, USA). RNA was quantified using a UV spectrophotometer (DU 800
Beckman Coulter, Brea, CA, USA). Five hundred nanograms of total RNA were used as template for
retrotranscription reaction by GoScript Reverse Kit (Promega, San Luis Obispo, CA, USA) according to
the manufacturer’s protocol. cDNA was used as template for Quantitative Real Time PCR analysis
(qPCR). The differential expression of AXIN2, GLI1, THY1 (also known as CD90), ITGAV, TEK and
ENPEP was validated in N- and P-CMSC and in BM-MSC cells. qPCR was also exploited to analyse the
expression of selected osteogenic genes as Runt-related transcription factor 2 (RUNX2), Alkaline phosphatase
(ALP), Osteonectin (ON), Osteopontin (OPN) and Osteocalcin (OCN). qPCR was performed using Syber
Green master mix (GoTaq qPCR Master Mix Kit, Promega, San Luis Obispo, CA, USA). The sequences
of all oligonucleotide primer pairs used for each gene are provided in Table 1. Each sample was
analysed in duplicate. The relative expression gene levels were normalised to Beta-actin (ACTB) levels
and quantified according to the ∆∆Ct method [56].
Table 1. Primer pairs for qPCR.
Gene Strand Sequence
ACTB FW ACGGCATCGTCACCAACT
ACTB REV AACGGCAGAAGAGAGAACCA
THY1 FW TCTCCTCCCAGAACGTCACA
THY1 REV GATGCCCTCACACTTGACCA
ITGAV FW TGTGGCTGTCGGAGATTTCA
ITGAV REV TTCCCAAAGTCCTTGCTGCT
TEK FW TGAACACAGTGGCTGGGATG
TEK REV GTGTCAATCACGTTTGGGGC
ENPEP FW TGCCAGTGGCGAAAGAAGAG
ENPEP REV ACAGCAAAGCACACCAGGTA
GLI1 FW TGCACCGAGGGCCCACTCTT
GLI1 REV AGGGAGCTGGGTGAGGTGCG
AXIN2 FW CCTGGCTCCAGAAGATCACA
AXIN2 REV TCAAGCTCTGAGCCTTCAGC
RUNX2 FW GAACCCAGAAGGCACAGACA
RUNX2 REV GGATGAGGAATGCGCCCTAA
ALP FW CCGTGGCAACTCTATCTTTGG
ALP REV GCCATACAGGATGGCAGTGA
ON FW TGCTCCCCAGGCAAAAGAAG
ON REV AGGGCTTGCACTTGACCAAA
OPN FW TGAAACGAGTCAGCTGGATG
OPN REV GCTCTCATCATTGGCTTTCC
OCN FW GACTGTGACGAGTTGGCTGA
OCN REV AGCAGAGCGACACCCTAGAC
FW, forward primer; REV, reverse primer.
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4.5. Histological Analyses
Suture tissue specimens harvested from patients, were fixed in 4% (w/v) formalin in phosphate
buffer 0.1 M at pH 7.2 for 72 h at 4 ◦C. After rinsing with running water, the samples were decalcified
in Decalcifier DC2 solution (#11028306 VWR Chemical, Radnor, PA, USA) for 24–96 h (based on
sample size) at 4 ◦C under constant agitation. The tissues were then washed in phosphate buffer saline
(PBS) 0.01 M pH 7.4 for 1–2 h at RT, and then cryoprotected in 15% sucrose in PBS overnight at 4 ◦C.
The samples were then embedded in OCT compound, and 10-µm-thick sections were cut on a cryostat
(CM 1850, Leica, Wetzlar, Germany) and directly mounted on slides. The slides were used both for
haematoxylin and eosin staining and for immunofluorescence analysis. In particular, for histological
analysis, the sections were incubated with haematoxylin (according to Mayer, 05-06002/L Bio-Optica,
Milan, Italy) for 5 min, washed in running water for 5 min, and then stained with eosin (05-10002/L
Bio-Optica, Milan, Italy) for 1 min. Finally, the sections were dehydrated through a series of graded
alcohols, clarified in xylene and cover-slipped with Eukitt mounting medium (03989 Sigma Aldrich,
Saint Louis, MO, USA). The slides were then examined using a Zeiss Axiophot microscope and
the images were captured with an AxioCam 503 colour camera (Zeiss, Jena, Germany) coupled to
the microscope.
4.6. Immunofluorescence Analysis
Immunofluorescence analysis was performed both on tissue sections and on formalin-fixed
CMSC cultures to visualise and quantify the expression of specific-lineage markers during osteogenic
induction. In particular, we analysed the expression of Ki-67, THY1, GLI1 and AXIN2. Cells were
first permeabilised with 0.3% Triton X-100 for 10 min. Then, both cells and tissue sections were
incubated with 3% bovine serum albumin (BSA) in PBS and 3% normal horse serum (NHS)/0.3% Triton
X-100 in PBS for 60 min at RT to block nonspecific binding sites. Subsequently, co-immunostainings
for AXIN2 or GLI1 with Ki-67 or THY1, respectively, were obtained using the following primary
antibodies: mouse anti-THY1 (#MA5-16671 ThermoFisher Scientific, Waltham, MA, USA, 1:100/1:200
respectively for tissue sections and cells), mouse anti-Ki-67 (only for tissue sections) (#ab8191 Abcam,
Cambridge, UK, 1.100), rabbit anti-AXIN2 (#PA5-21093 ThermoFisher Scientific, Waltham, MA, USA,
1:100 and 1:500, respectively, for tissue sections and cells) and rabbit anti-GLI1 (#ab49314 Abcam,
Cambridge, UK, 1:100 and 1:200, respectively, for tissue sections and cells). After incubating with
primary antibodies overnight at 4 ◦C and washing three times in PBS, the appropriate goat secondary
antibodies were added: Alexa Fluor 488 anti-mouse for THY1 and Ki-67 (#305-545-045 Jackson
Immunoresearch Laboratories, West Grove, PA, USA, 1:200) or Cy3 anti-rabbit for Gli1 and AXIN2
(#715-166-150 Jackson Immunoresearch Laboratories West Grove PA USA, 1:200) in PBS for 2 h at RT.
After further washing, cells were counterstained with DAPI and analysed using the Nikon confocal
laser scanning microscopy system (A1MP+, Nikon, Amsterdam, Netherlands) while tissue sections
were cover-slipped with Fluoromount Aqueous Mounting Medium (F4680 Sigma–Aldrich, Saint
Louis, MO, USA), examined and photographed under a Zeiss LSM 510 confocal laser scanning
microscopy system. At least five fields representing each slide were examined in duplicate for
each condition. Three non-consecutive tissue sections from each patient were processed for double
label immunofluorescence. The quantification of fluorescence intensity was analysed using ImageJ
program (NIH-https://imagej.nih.gov/ij/download.html). To verify and confirm the specificity of
the immunolabeling, primary antisera were omitted, and only secondary antibodies were used.
No immunoreactivity was detected.
4.7. AXIN2 Silencing in N-CMSC
Three chemically synthesised 27-mer Dicer-Substrate Short Interfering RNAs (DsiRNAs, TriFECTa
RNAi Kit #hs.Ri.AXIN 2.13, Integrated DNA Technologies, Coralville, IA, USA) were transfected
in N-CMSC to knockdown the expression of AXIN2 gene. To this aim, N-CMSC were plated in
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6-well plates at a seeding density of 80,000 cells/well and cultured with standard growth medium.
Two days after plating, cells at 70% of confluence were transfected with AXIN2-DsiRNAs using
Lipofectamine RNAiMAX Reagent (ThermoFisher Scientific, Waltham, MA, USA), according to
the manufacturer’s instructions. To test the efficacy of siRNAs constructs, we tested to different
concentrations (i.e., 30 and 20 nM). Since the higher concentration critically affected cell viability,
all the experiments were performed to a final concentration of 20 nM. After three days, the medium
was replaced with OM to induce the osteogenic differentiation. A second dose of AXIN2-DsiRNAs was
transfected when OM was replaced. N-CMSC treated exclusively with lipofectamine served as controls
for transfection. After 1 week of osteogenic induction, all samples were lysed for RNA extraction and
gene expression analysis by qPCR. P-CMSC cultured in both GM and OM were analysed comparatively.
4.8. Statistical Analysis
Data were analysed using GraphPad Prism software version 6.0 (San Diego, CA, USA). Results are
presented as means ± standard deviation (SD). Statistical differences between groups were analysed
using the unpaired Student’s t-test. All statistics were two-tailed and the level of significance was set
at p < 0.05.
5. Conclusions
Our data provide original evidence that GLI1 and AXIN2 reasonably represent specific stem cell
markers for the osteogenic niche of human calvarial bones. These findings may represent the foundation
for further studies aimed at implementing advanced therapies for skull bone reconstruction and at
studying the pathophysiology of altered stem cell mechanisms occurring in craniofacial inborn defect,
such as craniosynostosis. In this context, targeting GLI1- and AXIN2-expressing cells would represent
a strategy to modulate the proportion and activity of osteoprogenitor cells, hence the osteogenic niche
homeostasis, towards the development of patient-tailored approaches aimed at reducing the increased
osteogenic rate at the site of premature suture fusion.
Moreover, using nonsyndromic craniosynostosis as a model disease, this study supports the
idea of mechanistic effects of multifactorial aetiology underlying this condition, in which concurring
chemical and mechanical noxae in the environment can modulate the stem cell fate.
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